These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 24746904)

  • 41. Assessment of inflammation and fibrosis in non-alcoholic fatty liver disease by imaging-based techniques.
    Cobbold JF; Patel D; Taylor-Robinson SD
    J Gastroenterol Hepatol; 2012 Aug; 27(8):1281-92. PubMed ID: 22432836
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Editorial: Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis: An Epidemic that will Boost the Incidence of Cardiovascular Morbidity and Mortality.
    Athyros VG; Doumas M
    Curr Vasc Pharmacol; 2018; 16(3):206-208. PubMed ID: 29598814
    [No Abstract]   [Full Text] [Related]  

  • 43. Diagnosis and epidemiology of cirrhosis.
    Lefton HB; Rosa A; Cohen M
    Med Clin North Am; 2009 Jul; 93(4):787-99, vii. PubMed ID: 19577114
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Foreword. Nonalcoholic Fatty Liver Disease.
    Day CP; Anstee QM
    Semin Liver Dis; 2015 Aug; 35(3):203-6. PubMed ID: 26378638
    [No Abstract]   [Full Text] [Related]  

  • 45. How to Approach a Patient With Nonalcoholic Fatty Liver Disease.
    Tilg H
    Gastroenterology; 2017 Aug; 153(2):345-349. PubMed ID: 28647352
    [No Abstract]   [Full Text] [Related]  

  • 46. The liver's weighty problem.
    Leslie M
    Science; 2015 Jul; 349(6243):18-20. PubMed ID: 26138960
    [No Abstract]   [Full Text] [Related]  

  • 47. Prevention, diagnosis, and treatment of obesity. 2016 position statement of the Spanish Society for the Study of Obesity.
    Lecube A; Monereo S; Rubio MÁ; Martínez-de-Icaya P; Martí A; Salvador J; Masmiquel L; Goday A; Bellido D; Lurbe E; García-Almeida JM; Tinahones FJ; García-Luna PP; Palacio E; Gargallo M; Bretón I; Morales-Conde S; Caixàs A; Menéndez E; Puig-Domingo M; Casanueva FF
    Endocrinol Diabetes Nutr; 2017 Mar; 64 Suppl 1():15-22. PubMed ID: 27543006
    [No Abstract]   [Full Text] [Related]  

  • 48. Association of nonalcoholic fatty liver disease with cardiovascular risk factors in obese adolescents: the role of interdisciplinary therapy.
    Sanches PL; de Piano A; Campos RM; Carnier J; de Mello MT; Elias N; Fonseca FA; Masquio DC; da Silva PL; Corgosinho FC; Tock L; Oyama LM; Tufik S; Dâmaso AR
    J Clin Lipidol; 2014; 8(3):265-72. PubMed ID: 24793347
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Noninvasive assessment of liver fibrosis: serum markers, imaging, and other modalities.
    Guha IN; Rosenberg WM
    Clin Liver Dis; 2008 Nov; 12(4):883-900, x. PubMed ID: 18984472
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The assessment of cardiovascular risk factors in patients with nonalcoholic fatty liver disease].
    Chubirko KI; Ivachevs'ka VV; Hechko MM; Chopeĭ IV; Stan MP; Koshelia II
    Wiad Lek; 2014; 67(2 Pt 2):332-4. PubMed ID: 25796862
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Progress in the search for circulating biomarkers of nonalcoholic fatty liver disease.
    Amacher DE
    Biomarkers; 2014 Nov; 19(7):541-52. PubMed ID: 25189636
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Non-invasive diagnosis of advanced fibrosis and cirrhosis.
    Sharma S; Khalili K; Nguyen GC
    World J Gastroenterol; 2014 Dec; 20(45):16820-30. PubMed ID: 25492996
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [The fatty liver epidemic: An analysis from the primary care].
    Caballeria L; Torán P
    Aten Primaria; 2019 Nov; 51(9):525-526. PubMed ID: 31718777
    [No Abstract]   [Full Text] [Related]  

  • 54. In search of the optimal management strategy for non-alcoholic fatty liver disease in type 2 diabetes patients.
    Lee CH; Lui DT; Lam KS
    J Diabetes Investig; 2021 Apr; 12(4):482-484. PubMed ID: 32814360
    [No Abstract]   [Full Text] [Related]  

  • 55. Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China).
    Fan JG; Wei L; Zhuang H;
    J Dig Dis; 2019 Apr; 20(4):163-173. PubMed ID: 30444584
    [No Abstract]   [Full Text] [Related]  

  • 56. Non-alcoholic fatty liver disease: diagnosis and investigation.
    Nascimbeni F; Loria P; Ratziu V
    Dig Dis; 2014; 32(5):586-96. PubMed ID: 25034292
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Non-Invasive Diagnosis of Nonalcoholic Fatty Liver Disease.
    Yoneda M; Imajo K; Nakajima A
    Am J Gastroenterol; 2018 May; 113(10):1409-1411. PubMed ID: 29937542
    [No Abstract]   [Full Text] [Related]  

  • 58. A concise review of non-alcoholic fatty liver disease.
    Than NN; Newsome PN
    Atherosclerosis; 2015 Mar; 239(1):192-202. PubMed ID: 25617860
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Not Available].
    Rauh C; Dufour JF
    Ther Umsch; 2017 Jul; 74(3):87-92. PubMed ID: 28777051
    [No Abstract]   [Full Text] [Related]  

  • 60. Pediatric Nonalcoholic Fatty Liver Disease.
    Mitsinikos T; Mrowczynski-Hernandez P; Kohli R
    Pediatr Clin North Am; 2021 Dec; 68(6):1309-1320. PubMed ID: 34736591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.